ImmunoPrecise Antibodies Long Term Debt

ImmunoPrecise Antibodies (IPA) currently reports a long-term debt of $3.1M as of January 2026. That compares with $11M in the prior-year period — down 72.2% year over year. Use the charts on this page to explore ImmunoPrecise Antibodies's long-term debt history and peer comparisons.

ImmunoPrecise Antibodies's long-term debt decreased from $11M to $3.1M — a 72.2% year-over-year decrease (period ending January 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ImmunoPrecise Antibodies reported $3.1M in long-term debt as of January 2026. That compares with $11M in the prior-year period — down 72.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $3.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ImmunoPrecise Antibodies, and consider following IPA for alerts when major investors trade the stock.

ImmunoPrecise Antibodies is classified in the Healthcare sector. On long-term debt, it currently shows $3.1M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IPA with unrelated industries.